Hospitals Are Using YETI Coolers for Heart Transplants — TransMedics Just Built Something Better (TMDX Q1 2026) · Chip Stock Investor Podcast summary

Key takeaways

TransMedics is developing innovative organ preservation systems that could significantly improve transplantation outcomes and capture large market opportunities.
The new CHOPS cold preservation device is designed to serve a currently underserved segment of the heart transplant market, offering regulated, FDA-approved alternatives to non-regulated coolers.
European market expansion and new infrastructure could potentially double TransMedics’ total addressable market, supporting the company's growth trajectory.
Future plans include advancing kidney transplant technology with a new platform expected to launch around 2027, aiming to unlock thousands of additional transplants annually.
While there are risks involved, such as regulatory delays and market adoption challenges, the company's innovation pipeline and international expansion strategy present significant growth potential.

Summary

Introduction and Company Overview

The podcast begins with an overview of TransMedics' recent earnings report from May 5th, highlighting their goal to become a leading player in organ transplantation technology. The discussion emphasizes the company's focus on innovation, expansion, and addressing current market inefficiencies, such as the use of non-regulated coolers for heart preservation.

Product Innovation - The CHOPS Cold Preservation System

A significant portion of the episode discusses TransMedics' new CHOPS system, a cold preservation device designed for a segment of the heart transplant market where cold storage suffices. This device aims to improve organ preservation by extending the four-hour window typically used, thereby increasing the viability of hearts for transplant. It also serves as a control in their clinical trials and as a revenue source for transplant centers with limited budgets. The CEO defends this product as a genuine advancement, not just an inferior alternative to their existing warm perfusion systems, by underlining the current reliance on coolers like Yeti, which are unregulated and not FDA-approved for organ preservation.

Market Opportunity and Competitive Edge

The episode details the massive market potential: over 4,600 hearts transplanted in 2025, with roughly 2,100 preserved under four hours, which currently rely on non-regulated coolers. TransMedics' device offers a regulated, FDA-approved alternative that could revolutionize this segment. The company emphasizes that their system is not intended to cannibalize their existing market but to expand into areas where current solutions are inadequate or non-existent.

European Expansion Strategy

TransMedics is planning to expand into Europe by partnering with PAD Aviation in Germany and developing infrastructure in Italy, aiming to replicate their US success globally. This move could potentially double their overall market, leveraging new logistics capabilities and regional infrastructure.

Advancement in Kidney Transplant Technology and Future Plans

The company is developing a new platform (Gen 3.0) for kidney transplants, aiming for market entry around 2027, which could unlock over 20,000 transplants annually in the US and address the high discard rate of kidneys due to prolonged ischemic times. Parallel development tracks are ongoing for liver, heart, and lung systems, aiming to modernize their offerings and expand their impact.

Financial Highlights and Strategic Investments

In Q1 2026, TransMedics reported revenue of $174 million, a 21% year-over-year increase, with a significant portion of transplants supported by their logistics service. Their balance sheet shows around $462 million in cash, with ongoing investments in research, new infrastructure, and IT systems to support expansion and operational efficiency. The company has also reduced some debt from previous acquisitions.

Risks and Outlook for TransMedics

The host discusses potential risks, including the possibility of some initiatives not performing as expected, regulatory hurdles, market acceptance, and challenges in international expansion. Despite these risks, the overall outlook remains positive thanks to the promising product pipeline, market opportunities, and ongoing growth efforts.

Show notes

On the Q1 2026 earnings call for TransMedics, the CEO said something that stopped everyone in their tracks. Major transplant programs, he said, are going to Home Depot and buying YETI coolers to preserve human hearts before transplantation. None of those coolers are FDA-approved. None are validated for that purpose. That is the status quo TransMedics is trying to replace.

This is CSI's update on TransMedics following their May 5th earnings report. TransMedics is not a semiconductor company — it sits in CSI's small bets basket, a collection of positions outside the core semiconductor thesis that Kasey follows closely. The company is building what it describes as the premier program for organ transplantation, combining a warm perfusion technology called the Organ Care System with its own aviation logistics network to dramatically improve the odds that a donated organ reaches its recipient in viable condition.

The Q1 2026 numbers are solid. Revenue of $174 million, up 21% year over year, with 82% of organ transplants now covered by TransMedics' own logistics service. But the more interesting story is what comes next across four distinct growth catalysts.

First, the CHOPS system — a new cold preservation device TransMedics just developed to serve the segment of the heart transplant market where cold storage is sufficient and warm perfusion is not required. Of 4,646 hearts transplanted in 2025, roughly 2,100 were preserved for less than four hours. That entire segment is currently going to Home Depot coolers. CHOPS is also the control arm TransMedics needed to run the ENHANCE Heart clinical trials — a clever solution to the problem of not being able to find a competitor willing to run head-to-head against their warm perfusion system.

Second, European expansion — a logistics partnership with PAD Aviation in Germany and new infrastructure in Italy that could eventually double the total addressable market.

Third, the kidney opportunity. Over 20,000 deceased kidney transplants happen annually in the United States. Between 8,000 and 9,000 kidneys are discarded every year due to prolonged ischemic times. TransMedics has designed a Gen 3.0 OCS platform for kidney transplantation, targeting 2027 for market entry.

Fourth, the Gen 3.0 platform upgrade for liver, heart, and lung — parallel development tracks that modernize the core product across every organ.

Kasey closes with something genuinely useful: an honest accounting of what could go right and what could go wrong, and why she continues to hold a small position.

This episode was released to Semi Insider members several weeks before this public version. Members get Kasey and Nick's full research, live Q&A sessions, and analysis like this as it happens. Join at chipstockinvestor.com/membership

What we cover:

— The CHOPS cold preservation system and why it exists

— ENHANCE Heart trial — Part A and Part B explained

— Will CHOPS cannibalize OCS warm perfusion revenue? The CEO's answer

— Heart transplant market data — 2,131 hearts going to cold storage annually

— European expansion — PAD Aviation and Italy buildout

— The kidney opportunity — 20,000+ transplants, 8,000–9,000 discarded

— OCS Gen 3.0 — kidney platform targeting 2027

— Q1 2026 financials — $174M revenue, balance sheet, Summit Aviation debt

— What could go right and what could go wrong for TMDX

— CSI's current position and ongoing conviction

Disclosure: Kasey and Nick hold a position in TransMedics. This content is for general information only and is not individual investment advice. All investing involves risk.

chipstockinvestor.com

Hospitals Are Using YETI Coolers for Heart Transplants — TransMedics Just Built Something Better (TMDX Q1 2026)